Literature DB >> 8904874

The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis.

E S Choi1, M M Hokom, J L Chen, J Skrine, J Faust, J Nichol, P Hunt.   

Abstract

Thrombopoietin (TPO), the ligand for the c-Mpl cytokine receptor, is a recently identified cytokine with potent effects on platelet production. The receptor-binding portion of c-Mpl ligand is encompassed in another molecule known as megakaryocyte growth and development factor, or MGDF. Although it is clear that the administration of TPO or MGDF to animals dramatically increases the platelet count, the specific stage(s) of thrombopoiesis during which these molecules are principally active have not been unambiguously determined. Pharmacology studies administering MGDF at doses ranging from 0.1 to 630 micrograms/kg/d to mice revealed a biphasic response in platelet production. Administration of the drug at concentrations from 6 to 60 micrograms/kg/d resulted in platelet counts 5-fold above normal. However, doses > 60 micrograms/kg/d resulted in less-than-optimal platelet production. This phenomenon was investigated in vitro. Using an established culture system for the generation of human megakaryocytes and platelets, MGDF was shown to be optimally and equivalently active in the generation of mature megakaryocytes at concentrations from 10 to 1000 ng/ml. However, the cytokine was not required for proplatelet formation and in fact was inhibitory to that process in a dose-dependent manner. When MGDF was added to human megakaryocytes at concentrations of 200 ng/ml or greater, proplatelet formation was inhibited to 30% of control values. MGDF-mediated inhibition was specific, since the addition of the truncated form of the c-Mpl receptor reversed the inhibition in a dose-dependent manner. Other recombinant factors, interleukin-6, interleukin-11 and erythropoietin had no significant positive or negative effects in this human proplatelet assay. Together, these data suggest that although TPO and MGDF promote the full spectrum of megakaryocyte growth and development, they are not necessary for proplatelet formation, and may in part regulate platelet shedding by their absence.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8904874     DOI: 10.1046/j.1365-2141.1996.d01-1920.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

Review 1.  The end is just the beginning: megakaryocyte apoptosis and platelet release.

Authors:  J Li; D J Kuter
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

Review 2.  In vivo platelet production from mature megakaryocytes: does platelet release occur via proplatelets?

Authors:  Goro Kosaki
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

3.  The regulation of proplatelet production.

Authors:  Amy E Geddis
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

4.  Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.

Authors:  Ashley P Ng; Maria Kauppi; Donald Metcalf; Craig D Hyland; Emma C Josefsson; Marion Lebois; Jian-Guo Zhang; Tracey M Baldwin; Ladina Di Rago; Douglas J Hilton; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

Review 5.  Failing to live up to the fanfare? A personal perspective on obstacles to the clinical development of thrombopoietic agents.

Authors:  R L Basser; C G Begley
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

6.  Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl.

Authors:  Nan Xiao; Suparna Laha; Shankar P Das; Kayla Morlock; Jonathan L Jesneck; Glen D Raffel
Journal:  Blood       Date:  2014-12-02       Impact factor: 22.113

7.  Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.

Authors:  David J Kuter
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

Review 8.  Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Authors:  Roberto Stasi; Maria L Evangelista; Sergio Amadori
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Zinc finger protein, Hzf, is required for megakaryocyte development and hemostasis.

Authors:  Yuki Kimura; Adam Hart; Masanori Hirashima; Chen Wang; Doug Holmyard; Jackie Pittman; Xin-Li Pang; Carl W Jackson; Alan Bernstein
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

Review 10.  Transcription factors in late megakaryopoiesis and related platelet disorders.

Authors:  M R Tijssen; C Ghevaert
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.